As part of its plans, the company has decided to focus its Osaka plant to become a specialty manufacturing site for prostate and breast cancer drug Leuplin/Lupron (leuprorelin).
The Osaka Plant will continue to be a specialty manufacturing site for Leuplin, meanwhile, the Hikari Plant will further expand its capacity to produce several ethical drugs such as anticancer drugs and vaccines.
In order to optimize its global manufacturing network, the company will transfer the manufacturing of solid products to its plants at Hikari and Oranienburg, a process that will be completed during fiscal year 2018.
The company said that the Oranienburg Plant will further improve its capacity and continue to deliver products to many countries.
Takeda Pharmaceutical Production Division senior vice-president Tetsuo Miwa said: "Through our effort towards optimizing our global manufacturing network, our company will further enhance our productivity and streamline our global operations, as well as further reinforce our manufacturing and supply system for focus on timely delivery of our high quality products to patients and healthcare providers throughout the world."